Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- DEST.LSE
- Price
- -
- Stock movement down
- -1.00 (-25.00%)
- Company name
- Destiny Pharma PLC
- Exchange
- (LSE ,
- Currency
- GBX )
- Sector
- Healthcare >Biotechnology
- Market cap
- 287.31M
- Ent value
- 281.70M
- Price/Sales
- 345.51
- Price/Book
- 31.27
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -11.98%
- 1 year return
- -93.94%
- 3 year return
- -70.76%
- 5 year return
- -44.89%
- 10 year return
- -
Last updated: 2024-12-17
DIVIDENDS
DEST.LSE does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 345.51 |
| Price to Book | 31.27 |
| EV to Sales | 338.76 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 95.77M |
| EPS (TTM) | -0.06 |
| FCF per share (TTM) | -0.03 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 831.55K |
| Gross profit (TTM) | 825.36K |
| Operating income (TTM) | -6.74M |
| Net income (TTM) | -5.66M |
| EPS (TTM) | -0.06 |
| EPS (1y forward) | -8.50 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 99.25% |
| Operating margin (TTM) | -810.05% |
| Profit margin (TTM) | -680.30% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 6.38M |
| Net receivables | 899.73K |
| Total current assets | 7.60M |
| Goodwill | 0.00 |
| Intangible assets | 2.34M |
| Property, plant and equipment | 83.71K |
| Total assets | 9.96M |
| Accounts payable | 395.43K |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 768.32K |
| Total liabilities | 768.32K |
| Shareholder's equity | 9.19M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -2.46M |
| Capital expenditures (TTM) | 653.15K |
| Free cash flow (TTM) | -3.12M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -61.56% |
| Return on Assets | -56.81% |
| Return on Invested Capital | -61.56% |
| Cash Return on Invested Capital | -33.92% |
STOCK INFORMATION
Downside potential
Loading...
Downside potential data
| DEST.LSE | S&P500 | |
| Current price drop from All-time high | -98.72% | -5.59% |
| Highest price drop | -99.04% | -56.47% |
| Date of highest drop | 26 Jul 2024 | 9 Mar 2009 |
| Avg drop from high | -69.27% | -11.07% |
| Avg time to new high | 1750 days | 12 days |
| Max time to new high | 1749 days | 1805 days |
COMPANY DETAILS
Marketcap
287.31M
Marketcap category
Small-cap
Description
Destiny Pharma plc, a biotechnology company, focuses on the discovery, development, and commercialization of anti infectives in the United Kingdom. The company is involved in developing NTCD-M3 that is in Phase II clinical trial for the prevention of recurrent Clostridioides diffcile infections; XF-73 Nasal, which is in Phase II clinical trial for the prevention of post-surgical staphylococcal infection; and XF-73 Dermal that is in preclinical stage for the treatment of skin infections of antibiotic resistant bacteria, as well as superficial skin infections of antibiotic resistant bacteria. It also develops XF Drugs Research/Biofilms that is in preclinical stage for the treatment of antibiotic resistant biofilm and bacterial aggregate associated infections. Destiny Pharma plc has collaboration agreements with China Medical System Holdings Limited; SporeGen Limited; Sebela Pharmaceuticals; the University of Southampton; Aston University; the University of Sheffield; National Biofilms Innovation Centre; National Institute of Allergy and Infectious Diseases; Cystic Fibrosis Foundation; Cardiff University; and Tianjin Medical University. The company was incorporated in 1996 and is based in Brighton, the United Kingdom.
Employees
15
Investor relations
-
SEC filings
CEO
Country
UK
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
No items found